ArticleBiomaterials research2022
Biocompatible carbonized iodine-doped dots for contrast-enhanced CT imaging.
Article in Biomaterials research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 23 citations in OpenAlex.
- Fe-Doped Carbon Quantum Dots with Magneto-Fluorescent Dual Modality for Fluorescence and Magnetic Resonance Readouts.Sensors (Basel, Switzerland) · 2026Article
- Iodine-doped carbon dots for fluorescence/computed tomography imaging and photodynamic therapy of tumor cells.RSC advances · 2026Article
- Light-responsive nanotherapeutic carbon dots: a next generation tool for cancer phototherapy.Journal of the National Cancer Center · 2026Review
- Carbon dot-lipidoid nanocarriers for superiorly biocompatible nasal mRNA cancer vaccination.Journal of nanobiotechnology · 2025Article
- Sulfur-Doped Carbon Dots as a Highly Selective and Sensitive Fluorescent Probe for Copper Ion Detection in Biological Systems.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Toward the clinical translation of safe intravenous long circulating ILNEs contrast agent for CT imaging.Theranostics · 2025Article
- Emerging Trends in Nanomedicine: Carbon-Based Nanomaterials for Healthcare.Nanomaterials (Basel, Switzerland) · 2024Review
- X-Ray Visible Protein Scaffolds by Bulk Iodination.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Carbon Dots in Treatment of Pediatric Brain Tumors: Past, Present, and Future Directions.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundComputed tomography (CT) imaging has been widely used for the diagnosis and surveillance of diseases. Although CT is attracting attention due to its reasonable price, short scan time, and excellent diagnostic ability, there are severe drawbacks of conventional CT contrast agents, such as low sensitivity, serious toxicity, and complicated synthesis process. Herein, we describe iodine-doped carbon dots (IDC) for enhancing the abilities of CT contrast agents.
methodIDC was synthesized by one-pot hydrothermal synthesis for 4 h at 180 ℃ and analysis of its structure and size distribution with UV-Vis, XPS, FT-IR, NMR, TEM, and DLS. Furthermore, the CT values of IDC were calculated and compared with those of conventional CT contrast agents (Iohexol), and the in vitro and in vivo toxicities of IDC were determined to prove their safety.
resultsIDC showed improved CT contrast enhancement compared to iohexol. The biocompatibility of the IDC was verified via cytotoxicity tests, hemolysis assays, chemical analysis, and histological analysis. The osmotic pressure of IDC was lower than that of iohexol, resulting in no dilution-induced contrast decrease in plasma.
conclusionBased on these results, the remarkable CT contrast enhancement and biocompatibility of IDC can be used as an effective CT contrast agent for the diagnosis of various diseases compared with conventional CT contrast agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.